Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lifecore Biomedical (LFCR) Operating Expenses: 2009-2025

Historic Operating Expenses for Lifecore Biomedical (LFCR) over the last 15 years, with May 2025 value amounting to $11.1 million.

  • Lifecore Biomedical's Operating Expenses fell 26.71% to $11.1 million in Q2 2025 from the same period last year, while for May 2025 it was $53.1 million, marking a year-over-year increase of 4.79%. This contributed to the annual value of $50.6 million for FY2025, which is 0.27% down from last year.
  • Lifecore Biomedical's Operating Expenses amounted to $11.1 million in Q2 2025, which was down 7.82% from $12.0 million recorded in Q1 2025.
  • In the past 5 years, Lifecore Biomedical's Operating Expenses ranged from a high of $21.3 million in Q1 2022 and a low of $3.4 million during Q2 2022.
  • For the 3-year period, Lifecore Biomedical's Operating Expenses averaged around $13.3 million, with its median value being $12.9 million (2024).
  • As far as peak fluctuations go, Lifecore Biomedical's Operating Expenses crashed by 70.46% in 2022, and later surged by 320.44% in 2023.
  • Quarterly analysis of 5 years shows Lifecore Biomedical's Operating Expenses stood at $7.8 million in 2021, then surged by 42.01% to $11.0 million in 2022, then increased by 3.71% to $11.4 million in 2023, then climbed by 14.01% to $13.0 million in 2024, then declined by 26.71% to $11.1 million in 2025.
  • Its Operating Expenses stands at $11.1 million for Q2 2025, versus $12.0 million for Q1 2025 and $13.0 million for Q4 2024.